Showing results for : nuclear medicine therapy

The term 'theranostics' is an integration of the words 'therapeutics' and 'diagnostics'. Theranostic agents are paired agents, one an imaging agent that 'sees' the lesion and the other, a companion therapeutic agent that 'treats' the same lesions. While the concept of theranostics is widely used in various molecular probes in oncology, the most relevant application of theranostics is in nuclear medicine where it is called Radio-theranostics.

Oligometastatic prostate cancer (OMPC) that has five or fewer sites of metastasis is considered a transitional state between localized and widespread metastatic tumors. With improvements in diagnostic modalities such as functional imaging / PSMA PET-CT, OMPC is being diagnosed with greater frequency than ever before.

I am writing this blog to guide patients who would want to come to India for medical treatment. This is a step-by-step logistics guide and is entirely based on my experience and what steps I went through before landing in New Delhi, India for my treatment.

Transarterial Chemoembolisation or TACE has been the initial treatment modality for HCC and has a huge body of evidence from several studies and clinical trials. Therefore, for long TACE has been a preferred treatment algorithm for unresectable HCC

Yttrium-90 or Y90is a commonly used isotope in the medical field specially in departments like nuclear medicine and radiation oncology for radiation therapy. This radioisotope is relied upon to provide a prescribed amount of radiation to a targeted area , such as a tumor. One of the most common uses of Y90 is during an internal radiation therapy called radioembolization.

This overview provides the patient and the caregiver a peek at what to expect during a typical PRRT treatment with Lu177 (Lutathera) and it covers the following aspects of a typical PRRT treatment day:

PRRT or Peptide Receptor Radionuclide Therapy is a type of Nuclear Medicine Therapy in which a cell-targeting protein or peptide is combined with a small amount of radioactive material that created a special type of radiopharmaceutical known as a Radiopeptide. This radiopeptide is injected into a Neuroendocrine Tumor patient’s bloodstream.

Neuroendocrine tumours (NETs) are heterogeneous with varying behaviour. Treatment decisions are taken basis Histological studies plus imaging data and clinical studies. Surgery is a curative option for NET patients with localized well-differentiated tumours, for non-localized metastatic tumours, Surgery is not an option.

My last article (Which patients can benefit with PPRT?) summed up the fundamentals of Nuclear Medicine PRRT and which patients may benefit from this therapy. Today, I shall be giving you a low down on PRRT again, and we shall cover some details

For advanced prostate cancer patients or metastatic castration-resistant prostate cancer (mCRPC) patients, conventional treatment modalities, such as surgery, chemotherapy etc. might not prove to be highly effective in terms of controlling the spread of the cancer. This is where Nuclear Medicine and Molecular Imaging are playing an important part in the management of cancer and that too in a personalized manner.

For prostate cancer patients who have become refractory to conventional therapy, the department of Nuclear Medicine & Molecular Imaging at the Fortis Memorial Research Institute (FMRI) in India’s Gurugram is not only one of the World’s most advanced Nuclear Medicine Centre but is also the centre that offers the lowest cost for Lu177 PSMA Therapy.

TARE is a palliative treatment (it means that it does not provide a cure) that helps slow down the disease growth and also helps alleviate symptoms. It is often used as a treatment option for patients who cannot undergo other treatment options such as liver surgery or liver transplantation.

Cancer is an abnormal cellular growth in a specific body region that is able to spread internally and cover other areas. If left untreated, it causes a number of life-threatening conditions that may even lead to fatality.

The Nuclear Medicine Therapy Centre at Fortis Memorial Research Institute (FMRI) is the Only Centre in India Offering Myeloblative MIBG Therapy for High Risk Neuroblastomas in Children.

In the past one year, the Nuclear Oncology Experts team at the Department of Nuclear Medicine at Fortis Memorial Research Institute has treated 30 new patients of Castrate Resistant Prostate Cancer (CRPC) with Ac225 PSMA Therapy (Targeted Alpha Therapy). And the results are similar to the results being achieved by most good Nuclear Medicine Centres across the world – 75-80% of the patients have shown evidences of a significant Radiological and Biochemical Response with prolonged duration of response.